AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Merlin

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P35240

UPID:

MERL_HUMAN

Alternative names:

Moesin-ezrin-radixin-like protein; Neurofibromin-2; Schwannomerlin; Schwannomin

Alternative UPACC:

P35240; O95683; Q8WUJ2; Q969N0; Q969Q3; Q96T30; Q96T31; Q96T32; Q96T33; Q9BTW3; Q9UNG9; Q9UNH3; Q9UNH4

Background:

Merlin, also known as Neurofibromin-2, plays a crucial role in the Hippo/SWH signaling pathway, pivotal for tumor suppression by promoting apoptosis and restricting proliferation. It functions as a membrane stabilizing protein and may inhibit PI3 kinase, highlighting its significance in cellular regulation and tumorigenesis prevention.

Therapeutic significance:

Merlin's involvement in diseases such as Neurofibromatosis 2, Schwannomatosis 1, and malignant Mesothelioma underscores its therapeutic potential. Targeting Merlin's pathway could lead to innovative treatments for these conditions, emphasizing the importance of further research into its mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.